Reference number(s)
6737-A

Specialty Guideline Management
Revuforj

Products Referenced by this Document

Drugs that are listed in the following table include both brand and generic and all dosage forms and strengths unless otherwise stated. Over-the-counter (OTC) products are not included unless otherwise stated.

Brand Name	Generic Name
Revuforj	revumenib

Indications

The indications below including FDA-approved indications and compendial uses are considered a covered benefit provided that all the approval criteria are met and the member has no exclusions to the prescribed therapy.

FDA-approved Indications[1]

Revuforj is indicated for the treatment of relapsed or refractory acute leukemia with a lysine methyltransferase 2A gene (KMT2A) translocation in adult and pediatric patients 1 year and older.

Documentation

Submission of the following information is necessary to initiate the prior authorization review: KMT2A translocation status.

Reference number(s)
6737-A

Coverage Criteria

Acute Leukemia[1]

Authorization of 12 months may be granted for treatment of relapsed or refractory acute leukemia with a KMT2A translocation as a single agent when the member does not have BCR::ABL1-positive B-cell acute lymphoblastic leukemia (B-ALL).

Continuation of Therapy

Authorization of 12 months may be granted for continued treatment in members requesting reauthorization for an indication listed in the coverage criteria section when there is no evidence of unacceptable toxicity or disease progression while on the current regimen.

References

1. Revuforj [package insert]. New York, NY: Syndax Pharmaceuticals, Inc.; April 2025.
2. The NCCN Drugs & Biologics Compendium® © 2025 National Comprehensive Cancer Network, Inc. http://www.nccn.org. Accessed July 7, 2025.